Langer-Gould AM, Smith JB, Nielsen AS, Beaber BE, et al. De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler 2026 Mar 19:13524585261430130. doi: 10.1177/13524585261430130.
PMID: 41852088